Ankyra Therapeutics and Jenga Biosciences Announce Exclusive License Agreement for JEN-101
Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101).
- Ankyra Therapeutics and Jenga Biosciences are pleased to announce today an exclusive license agreement to develop and commercialize JEN-101 (formerly known as cANK-101).
- Ankyra will receive an upfront payment and Jenga will take the lead on further development and commercialization of JEN-101.
- Julia Stephanus, Executive Chair of Jenga Biosciences and Partner at Borealis Ventures, expressed enthusiasm for the licensing agreement with Ankyra.
- "Jenga is dedicated to developing safe and effective drugs for canine cancer, an area with substantial demand for advancements and tremendous need.